Lorenc Tomasz, Kocoń Hanna, Gołębiowski Marek
1 Department of Clinical Radiology, Medical University of Warsaw, Poland.
Department of Orthopedics and Traumatology of the Musculoskeletal System, Medical University of Warsaw, Poland.
Pol J Radiol. 2021 Jan 12;86:e19-e30. doi: 10.5114/pjr.2021.102678. eCollection 2021.
The impact of computed tomography (CT)-guided, percutaneous radiofrequency ablation and interstitial laser ablation (ILA) on the management of patients with osteoid osteoma was studied. This was carried out by assessing immediate and long-term clinical outcomes, the complication rate, and repeat therapy effectiveness in recurrent patients who have already experienced percutaneous ablation.
Consecutive patients with osteoid osteoma were assessed before the interventional treatment in a single centre from 2010 to 2015. Patient demographics, complications, and recurrence were recorded. The pain was evaluated with Visual Analogue Scale (VAS). Percutaneous procedures were performed by means of radiofrequency thermoablation or ILA. Epidural or regional anaesthesia in the CT suite was applied in all procedures. Success, whether primary or secondary, was measured as complete pain relief without evidence of recurrence after the first or second procedure, respectively. Osteoid osteoma characteristics, procedure overview, and technical success were looked for in pre-procedural and procedural scans.
Eighty-three per cent of osteoid osteomas were located in lower extremities, 56% of tumours were intracortical, and 83% of osteoid osteomas were extra-articular. The mean pre-procedure VAS score was 8.5 ± 0.8, while the overall primary success rate of radiofrequency thermoablation and ILA was 87.5%. No major complications were noted. The mean follow-up period for patients in was 7.5 years (5.0-10.2 years).
Percutaneous, CT-guided thermoablation proved to be effective and should become the method of choice in osteoid osteoma treatment because of its minimal invasiveness. Our results show that there is no risk of very late recurrence after achieving primary and secondary treatment success.
研究计算机断层扫描(CT)引导下经皮射频消融和间质激光消融(ILA)对骨样骨瘤患者治疗的影响。通过评估直接和长期临床结果、并发症发生率以及对已经接受过经皮消融的复发患者的重复治疗效果来进行此项研究。
对2010年至2015年在单一中心接受介入治疗前的连续性骨样骨瘤患者进行评估。记录患者的人口统计学资料、并发症和复发情况。采用视觉模拟评分法(VAS)评估疼痛程度。经皮操作通过射频热消融或ILA进行。所有操作均在CT室实施硬膜外或区域麻醉。初次或二次治疗成功的衡量标准分别为首次或第二次手术后疼痛完全缓解且无复发迹象。在术前和术中扫描中查找骨样骨瘤特征、操作概述和技术成功情况。
83%的骨样骨瘤位于下肢,56%的肿瘤位于皮质内,83%的骨样骨瘤位于关节外。术前VAS评分的平均值为8.5±0.8,而射频热消融和ILA的总体初次成功率为87.5%。未发现重大并发症。患者的平均随访期为7.5年(5.0 - 10.2年)。
CT引导下经皮热消融被证明是有效的,因其微创性应成为骨样骨瘤治疗的首选方法。我们的结果表明,在初次和二次治疗成功后不存在非常晚期复发的风险。